Thiruvananthapuram

27°C

Light Rain

Enter word or phrase

Look for articles in

Last Updated Wednesday July 24 2019 04:46 AM IST

Ratan Tata invests in two more startups

Text Size
Your form is submitted successfully.

Recipient's Mail:*

( For more than one recipient, type addresses seperated by comma )

Your Name:*

Your E-mail ID:*

Your Comment:

Enter the letters from image :

Ratan Tata Ratan Tata. File photo

Bengaluru: Tata Sons Chairman Emeritus Ratan Tata on Monday announced investing an unspecified amount in two more startups Moglix and Invictus Onclogy, which are based in New Delhi.

As an e-commerce firm, Moglix specialises in procurement of industrial products in business-to-business (B2B) space, while medical firm Invictus is an innovation-driven firm developing next-generation cancer therapeutics.

By investing in Moglix, Tata has forayed into a manufacturing tech-startup as an investor, adding to his varied portfolio of e-commerce and new-age tech-enabled firms.

"With his expertise in the manufacturing sector, Tata will play an important role in mentoring Moglix on business growth, global expansion and leadership," the company said in a statement.

Founded by Rahul Garg, an ex-Google geek, Moglix is focused on disrupting B2B industrial products space for suppliers and buyers the world over.

"We are pleased to have an icon of Indian manufacturing as our advisor. Tata's contribution to the manufacturing sector has been inspirational and we look forward to his guidance to steer the company in transforming the buying and selling process for manufacturers across the country," Garg said in a statement.

Moglix recently raised undisclosed pre-series A funding from venture fund Accel Partners and Jungle Ventures to enhance its e-platform, build a wider supplier base and increase marketing spend across Asia.

In Invictus, Tata has invested as part of its series A financing round along with institutional investors Navam Capital and Aarin Capital.

"The funds will be used to advance our lead molecule to complete phase-one clinical studies and to file a second investigational new drug application, which translates into substantial value inflections for us over the next 18 months," Oncology said in a statement.

Invictus Oncology employs a supra-molecular technology platform to design anti-cancer drugs that home into the tumour and modulate the tumour immune response.

"Tata's investment is an affirmation of the technology quality we have developed. We are getting good traction from investors in India and overseas," Oncology co-founder and Harvard Medical School assistant professor Shiladiyta Sengupta said in the statement.

In the past 18 months, Tata has invested in a slew of start-ups, including Infinite Analytics Inc., Snapdeal, Paytm, Ola, Tracxn Technologies, Dogspot.in and Zivame.

(With agency inputs)

Your form is submitted successfully.

Recipient's Mail:*

( For more than one recipient, type addresses seperated by comma )

Your Name:*

Your E-mail ID:*

Your Comment:

Enter the letters from image :

Disclaimer

The comments posted here/below/in the given space are not on behalf of Manorama. The person posting the comment will be in sole ownership of its responsibility. According to the central government's IT rules, obscene or offensive statement made against a person, religion, community or nation is a punishable offense, and legal action would be taken against people who indulge in such activities.

Email ID:

User Name:

User Name:

News Letter News Alert
News Letter News Alert